ERBB2 and hyperinsulinemic hypoglycemia, familial, 4: Likewise, in recent years, new predictive biomarkers of response in mCRC have emerged, such as microsatellite instability–high (MSI-H)/mismatch repair deficiency (dMMR) in immunotherapy [12]; mutation in BRAFV600E in the combination of anti-BRAF and anti-EGFR treatments [13]; and HER2 overexpression in anti-HER2 therapy [14].